加替沙星治疗解脲支原体性尿道炎的临床疗效观察：一项开放性临床试验。
Effect of gatifloxacin against Mycoplasma genitalium-related urethritis: an open clinical trial.
机构信息
Department of Urology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka 807-8555, Japan.
出版信息
Sex Transm Infect. 2011 Aug;87(5):389-90. doi: 10.1136/sti.2010.048553. Epub 2011 Apr 28.
OBJECTIVES
Mycoplasma genitalium and Chlamydia trachomatis are the primary pathogens detected from non-gonococcal urethritis (NGU). In this study, the efficacy of gatifloxacin was examined against M genitalium-related urethritis.
METHODS
The study was an open clinical trial evaluating the effectiveness of gatifloxacin with 200 mg doses twice a day for 7 days against male NGU.
RESULTS
Between March and September 2008, 169 male patients were enrolled, and microbiological and clinical cure rates could be evaluated in 86 patients detected with C trachomatis or M genitalium and in 135 with NGU, respectively. Microbiological cure rates of gatifloxacin against C trachomatis and M genitalium were 100% and 83%, respectively, and the total clinical cure rate was 99%.
CONCLUSION
Analysis of in-vivo and in-vitro data from the literature of fluoroquinolone efficacies against M genitalium suggests that a MIC90 of 0.125 μg/ml or less may be useful for optimal activity against M genitalium infection.
目的
生殖支原体和沙眼衣原体是从非淋球菌性尿道炎（NGU）中检测到的主要病原体。本研究旨在检测加替沙星治疗生殖支原体相关性尿道炎的疗效。
方法
这是一项开放的临床试验，评估了加替沙星 200mg 剂量、每日两次、连续 7 天治疗男性 NGU 的效果。
结果
2008 年 3 月至 9 月期间，共纳入 169 名男性患者，对 86 名同时检测到沙眼衣原体或生殖支原体的患者和 135 名 NGU 患者进行了微生物学和临床疗效评估。加替沙星对沙眼衣原体和生殖支原体的微生物学治愈率分别为 100%和 83%，总临床治愈率为 99%。
结论
对生殖支原体药敏的体内和体外数据的分析表明，MIC90 为 0.125μg/ml 或更低可能对生殖支原体感染具有最佳的活性。
Zotero 插件